Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials.

导出 OA

翻译打印收藏纠错

作者： Safi U,Khan ^[1] ; Muhammad U,Khan ^[1] ; Shahul,Valavoor ^[1] ; Muhammad Shahzeb,Khan ^[2] ; Victor,Okunrintemi ^[3] ; Mamas A,Mamas ^[4] ; Thorsten M,Leucker ^[5] ; Michael J,Blaha ^[6] ; Erin D,Michos ^[6]

作者单位： Department of Medicine, West Virginia University, Morgantown, WV, USA. ^[1] Department of Medicine, John H. Stroger J. Hospital of Cook County, Chicago, IL, USA. ^[2] Department of Internal Medicine, East Carolina University, Greenville, SC, USA. ^[3] Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, Staffordshire, UK. ^[4] Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, UK. ^[5] Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. ^[6]

关键词 Apolipoprotein B cardiovascular outcomes meta-regression analysis mortality

主题词载脂蛋白B类(Apolipoproteins B);心血管疾病(Cardiovascular Diseases);人类(Humans);降血脂药物(Hypolipidemic Agents);预后(Prognosis);危险因素(Risk Factors)

DOI 10.1177/2047487319871733

PMID 31475865

发布时间 2021-08-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交